UNSPSC 51282011: Chloramphenicol stearate

This classification denotes a protein synthesis inhibitor and antibiotic C29H46Cl2N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DL2A9M9D6X, chemically known as octadecanoic acid, (2r,3r)-2-((2,2-dichloroacetyl)amino)-3-hydroxy-3-(4-nitrophenyl)propyl ester, but more generally known as chloramphenicol stearate, which bears US NIH Compound Identifier 83945. European Medicines Agency schedules Chloramphenicol stearate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26903.

Most nations, for tariff and trade purposes, schedule chloramphenicol stearate under HS 29414000 and SITC 54139. As of Q4 2014, CHLORAMPHENICOL STEARATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCCCCCCCCCCCCCCC(=O)OC[C@H]([C@@H](C1CCC(CC1)[N+](=O)[O-])O)NC(=O)C(CL)CL.

UNSPSC 51282011 Chloramphenicol stearate is a Commodity code covering a specific pharmaceutical active ingredient that state and local procurement entities acquire as part of broader generic and specialty pharmaceutical sourcing agreements. Based on recent solicitation activity, state and local governments procure this and related compounds through cooperative purchasing vehicles that aggregate demand across multiple jurisdictions and facility types, negotiating pricing and supply relationships with manufacturers through authorized pharmaceutical wholesalers. The scope of work involves manufacturers providing comprehensive product information, maintaining compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, managing pricing through multiple formats (fixed price, net price bands, or WAC-minus structures), and fulfilling supply commitments to state and local health systems, correctional facilities, and public health programs.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon. MMCAP is the primary issuing body visible in recent activity under this code. Vendors must maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencala, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), supply products with specific National Drug Codes and packaging configurations, maintain insurance coverage including $5,000,000 commercial general liability per occurrence, and accept a 3 percent administrative fee on all contract purchases. The resulting agreements are effective July 1, 2026, with a two-year initial term for new responders and optional extensions at MMCAP's discretion. Evaluation is weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 5 percent each on administrative compliance, EDI capability, and acceptance of the 3 percent administrative fee.